Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Inventory (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Inventory for 17 consecutive years, with $492.7 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 14.83% to $492.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $492.7 million through Dec 2025, up 14.83% year-over-year, with the annual reading at $492.7 million for FY2025, 14.83% up from the prior year.
  • Inventory hit $492.7 million in Q4 2025 for Integra Lifesciences Holdings, up from $489.1 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $492.7 million in Q4 2025 to a low of $311.1 million in Q3 2022.
  • Historically, Inventory has averaged $381.3 million across 5 years, with a median of $360.3 million in 2023.
  • Biggest five-year swings in Inventory: dropped 9.79% in 2021 and later rose 20.03% in 2023.
  • Year by year, Inventory stood at $317.4 million in 2021, then grew by 2.27% to $324.6 million in 2022, then grew by 20.03% to $389.6 million in 2023, then increased by 10.13% to $429.1 million in 2024, then rose by 14.83% to $492.7 million in 2025.
  • Business Quant data shows Inventory for IART at $492.7 million in Q4 2025, $489.1 million in Q3 2025, and $465.1 million in Q2 2025.